Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1952 3
1956 1
1957 1
1961 1
1962 1
1975 1
1979 1
1980 1
1994 2
1995 1
1996 3
1997 5
1998 1
1999 3
2001 2
2002 5
2003 2
2004 7
2005 4
2006 4
2007 10
2008 10
2009 5
2010 11
2011 12
2012 10
2013 18
2014 10
2015 16
2016 12
2017 14
2018 16
2019 16
2020 16
2021 19
2022 13
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Amaria RN, et al. Among authors: bello d. Nature. 2022 Nov;611(7934):155-160. doi: 10.1038/s41586-022-05368-8. Epub 2022 Oct 26. Nature. 2022. PMID: 36289334 Free PMC article. Clinical Trial.
Biomarkers in long COVID-19: A systematic review.
Lai YJ, Liu SH, Manachevakul S, Lee TA, Kuo CT, Bello D. Lai YJ, et al. Among authors: bello d. Front Med (Lausanne). 2023 Jan 20;10:1085988. doi: 10.3389/fmed.2023.1085988. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36744129 Free PMC article.
Adjuvant immunotherapy for melanoma.
Thomas D, Bello DM. Thomas D, et al. Among authors: bello dm. J Surg Oncol. 2021 Mar;123(3):789-797. doi: 10.1002/jso.26329. J Surg Oncol. 2021. PMID: 33595889 Review.
Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma.
Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Amaria RN, et al. Among authors: bello d. Nature. 2023 Mar;615(7953):E23. doi: 10.1038/s41586-023-05892-1. Nature. 2023. PMID: 36894629 Free PMC article. No abstract available.
Updates in the management and future landscape of urothelial carcinoma.
Hanna KS, Campbell M, Kolling A, Husak A, Sturm S, Bello D, Blake K. Hanna KS, et al. Among authors: bello d. J Oncol Pharm Pract. 2021 Mar;27(2):435-444. doi: 10.1177/1078155220971026. Epub 2020 Nov 3. J Oncol Pharm Pract. 2021. PMID: 33143526 Review.
Melanoma mutagenesis and aberrant cell signaling.
Bello DM, Ariyan CE, Carvajal RD. Bello DM, et al. Cancer Control. 2013 Oct;20(4):261-81. doi: 10.1177/107327481302000404. Cancer Control. 2013. PMID: 24077403 Free article. Review.
Assessment and Mitigation of Exposure of 3-D Printer Emissions.
Kim B, Shin JH, Kim HP, Jo MS, Kim HS, Lee JS, Lee HK, Kwon HC, Han SG, Kang N, Gulumian M, Bello D, Yu IJ. Kim B, et al. Among authors: bello d. Front Toxicol. 2022 Feb 18;3:817454. doi: 10.3389/ftox.2021.817454. eCollection 2021. Front Toxicol. 2022. PMID: 35295129 Free PMC article.
231 results